Form 4 for BCRX BIOCRYST PHARMACEUTICALS INC
Accepted 2024-12-16 00:00:00 ET · period of report 2024-12-13 · accession 0001127602-24-029494 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-16 | 2024-12-13 | BCRX | Hutson Nancy J | Dir | S - Sale | $7.54 | -7,000 | 86.6K | -7% | -$52.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-13 | S | D | 7,000 | $7.54 | 86,638 | D | — | — | (F1) These shares were sold pursuant to a plan adopted by the Reporting Person on June 18, 2024 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, for the sole purpose of generating sufficient proceeds to cover the tax liability incurred in connection with the vesting of 16,745 restricted stock units. The sale occurred automatically and does not represent a discretionary transaction by the Reporting Person. (F2) The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.510 to $7.565. The Reporting Person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. |